- Home
- IBRX vs CENTA Comparison
IBRX vs CENTA Comparison
Compare IBRX & CENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- CENTA
- Stock Information
- Founded
- IBRX 2014
- CENTA 1955
- Country
- IBRX United States
- CENTA United States
- Employees
- IBRX N/A
- CENTA N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- CENTA Consumer Specialties
- Sector
- IBRX Health Care
- CENTA Consumer Discretionary
- Exchange
- IBRX Nasdaq
- CENTA Nasdaq
- Market Cap
- IBRX 2.4B
- CENTA 2.0B
- IPO Year
- IBRX N/A
- CENTA 1993
- Fundamental
- Price
- IBRX $2.87
- CENTA $30.44
- Analyst Decision
- IBRX Strong Buy
- CENTA Buy
- Analyst Count
- IBRX 5
- CENTA 4
- Target Price
- IBRX $11.40
- CENTA $37.00
- AVG Volume (30 Days)
- IBRX 10.1M
- CENTA 310.7K
- Earning Date
- IBRX 08-11-2025
- CENTA 08-06-2025
- Dividend Yield
- IBRX N/A
- CENTA N/A
- EPS Growth
- IBRX N/A
- CENTA N/A
- EPS
- IBRX N/A
- CENTA 1.87
- Revenue
- IBRX $31,222,000.00
- CENTA $3,155,810,000.00
- Revenue This Year
- IBRX $567.98
- CENTA $0.42
- Revenue Next Year
- IBRX $160.56
- CENTA $1.77
- P/E Ratio
- IBRX N/A
- CENTA $15.98
- Revenue Growth
- IBRX 10238.41
- CENTA N/A
- 52 Week Low
- IBRX $1.83
- CENTA $27.70
- 52 Week High
- IBRX $7.63
- CENTA $37.31
- Technical
- Relative Strength Index (RSI)
- IBRX 49.40
- CENTA 42.48
- Support Level
- IBRX $2.77
- CENTA $29.99
- Resistance Level
- IBRX $3.24
- CENTA $31.33
- Average True Range (ATR)
- IBRX 0.23
- CENTA 0.77
- MACD
- IBRX -0.03
- CENTA -0.17
- Stochastic Oscillator
- IBRX 19.74
- CENTA 18.29
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About CENTA Central Garden & Pet Company Nonvoting
Central Garden & Pet Co understands that home is central to life and has nurtured happy and healthy homes for over forty years. The segments of the company are the pet segment and garden segment. The company's trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier and communities grow stronger. Central is home to a portfolio of more than sixty-five brands including Pennington, Nylabone, Kaytee, Amdro, and Aqueon, manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central Garden and Pet is based in Walnut Creek, California, and has offices across North America and Europe.